Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of MB1707 in Advanced Cancer
NCT05465590Phase 1Withdrawn
- Sponsor
- Mainline Biosciences
- Start
- Dec 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Peptide-Drug Conjugates
01
Overview
Phase 1, open-label, single-arm trial of mb1707 in solid tumor (advanced stage), breast cancer, non-small cell lung cancer (NSCLC) and 2 more, sponsored by Mainline Biosciences. Primary endpoints: Incidence of Adverse Events at 14 days, Peak Plasma Concentration at 2 days and 6 more. Planned start Dec 2022; status: withdrawn.
02
Drugs
mb1707
03
Conditions
solid tumor (advanced stage)breast cancernon-small cell lung cancer (NSCLC)ovarian cancerpancreatic neoplasm
Beyond the preview
Go deeper on NCT05465590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05465590.